Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

20102,279 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 376, Issue 9737, pp. 245-251

Field-Weighted Citation Impact: 98.04